Search Result

Isoforms Recommended:	MEK1

Results for "

MEK1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (20) Aryl Hydrocarbon Receptor (1) Autophagy (12) Beta-secretase (2) c-Met/HGFR (1) Calcium Channel (1) Caspase (1) CDK (2) Cholinesterase (ChE) (2) E3 Ligase Ligand-Linker Conjugates (2) EGFR (1) Endogenous Metabolite (2) ERK (11) FLT3 (2) GSK-3 (2) HDAC (1) Influenza Virus (2) Isotope-Labeled Compounds (2) JAK (2) Ligands for Target Protein for PROTAC (2) MEK (56) Mitophagy (2) p38 MAPK (1) PDGFR (1) PERK (2) PI3K (4) Pim (1) PKC (1) PROTACs (3) Raf (4) Reactive Oxygen Species (2) TGF-beta/Smad (1) VEGFR (3)
By Research Areas:	Cancer (70) Cardiovascular Disease (4) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (4)

By Targets:

Akt (1)

Apoptosis (20)

Aryl Hydrocarbon Receptor (1)

Autophagy (12)

Beta-secretase (2)

c-Met/HGFR (1)

Calcium Channel (1)

Caspase (1)

CDK (2)

Cholinesterase (ChE) (2)

E3 Ligase Ligand-Linker Conjugates (2)

EGFR (1)

Endogenous Metabolite (2)

ERK (11)

FLT3 (2)

GSK-3 (2)

HDAC (1)

Influenza Virus (2)

Isotope-Labeled Compounds (2)

JAK (2)

Ligands for Target Protein for PROTAC (2)

MEK (56)

Mitophagy (2)

p38 MAPK (1)

PDGFR (1)

PERK (2)

PI3K (4)

Pim (1)

PKC (1)

PROTACs (3)

Raf (4)

Reactive Oxygen Species (2)

TGF-beta/Smad (1)

VEGFR (3)

By Research Areas:

Cancer (70)

Cardiovascular Disease (4)

Inflammation/Immunology (6)

Metabolic Disease (2)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15202

Binimetinib 25+ Cited Publications MEK162; ARRY-162; ARRY-438162	MEK Autophagy	Cancer
Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active *MEK1/2* kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 ^[1].

HY-14691

Refametinib 10+ Cited Publications BAY 869766; RDEA119	MEK	Cancer
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric *MEK1/MEK2* inhibitor with IC₅₀s of 19 nM and 47 nM, respectively.

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by *MEK1* with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable ^[1].

HY-145701

MEK1/2-IN-2	MEK	Cancer
MEK1/2-IN-2 is a potent ATP-competitive *MEK1/2* inhibitor and shows equipotent inhibition of WT MEK1/2 and a panel of MEK1/2 mutant cell lines ^[1].

HY-157750

MEK1/C-Raf-IN-1	MEK Raf	Cancer
MEK1/C-Raf-IN-1 (Compound 14d) is a *MEK1/C-Raf* inhibitor with IC₅₀ values of 97 and 23 nM, respectively. MEK1/C-Raf-IN-1 has antitumor activity ^[1].

HY-153864

*PROTAC MEK1* Degrader-1**	PROTACs MEK ERK	Cancer
PROTAC MEK1 Degrader-1 is a PROTAC targeting *MEK1* with a pIC₅₀ value of 7.0. PROTAC MEK1 Degrader-1 consists of a *MEK1* inhibitor and a von Hippel-Lindau ligand. PROTAC MEK1 Degrader-1 can inhibit *ERK1/2* phosphorylation. PROTAC MEK1 Degrader-1 shows an antiproliferative activity against A375 cells ^[1].

HY-P10074

TAT-MEK1	ERK	Inflammation/Immunology
TAT-MEK1 is an inhibitor ofERK2, consisting of TAT and MEK1 (N-terminal), TAT (YGRKKRRQRRR) derived from human immunodeficiency (HIV-1) transcriptional trans activator (TAT), is a cell-penetrating peptide. TAT-MEK1 IC₅₀ in vitro for ERK2 is 29 μM ^[1] .

HY-P4136

*Myristoyl-MEK1* Derived Peptide Inhibitor 1**	ERK	Cancer
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits ERK activation with an IC₅₀ of 10 μM ^[1].

HY-P5977

*STE-MEK1(13)* Ste-MPKKKPTPIQLNP-NH₂; ERK Activation Inhibitor Peptide	ERK	Cancer
STE-MEK1(13) (Ste-MPKKKPTPIQLNP-NH ) is a cell permeable *ERK1/2* inhibitor (IC₅₀: 13-30 μM). STE-MEK1(13) inhibits ERK1/2 phosphorylation ^[1] .

HY-13064A

Cobimetinib hemifumarate 40+ Cited Publications GDC-0973 hemifumarate; XL-518 hemifumarate	MEK Apoptosis	Cancer
Cobimetinib hemifumarate is a novel selective *MEK1* inhibitor, and the IC₅₀ value against MEK1 is 4.2 nM.

HY-13064

Cobimetinib 40+ Cited Publications GDC-0973; XL518	MEK Apoptosis	Cancer
Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-50706

Selumetinib 60+ Cited Publications AZD6244; ARRY-142886	MEK Apoptosis	Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral *MEK1/2* inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-50706A

Selumetinib sulfate 60+ Cited Publications AZD6244 sulfate; ARRY-142886 sulfate	MEK Apoptosis	Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2* inhibitor,* with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-13064S1

Cobimetinib-d4 hydrochloride GDC-0973-d₄ hydrochloride; XL518-d₄ hydrochloride	MEK Apoptosis Isotope-Labeled Compounds	Cancer
Cobimetinib-d₄ hydrochloride is deuterated labeled Cobimetinib (HY-13064). Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-107619

PD-334581	MEK	Cancer
PD-334581 is a *MEK1* inhibitor ^[1].

HY-132844

Tunlametinib HL-085	MEK	Cancer
Tunlametinib, an antineoplastic agent, is a MEK1/2 inhibitor ^[1].

HY-12058

AZD8330 5+ Cited Publications ARRY-424704; ARRY-704	MEK	Cancer
AZD8330 (ARRY-424704) is a potent, uncompetitive *MEK1/MEK2* inhibitor, with an IC₅₀ of 7 nM.

HY-12447

SMK-17	MEK Apoptosis	Cancer
SMK-17 is a selective, non-ATP-competitive *MEK1/MEK2* inhibitor with IC₅₀s of 62 nM and 56 nM, respectively. SMK-17 binds to the allosteric pocket of MEK1/2. SMK-17 induces apoptosis in tumor cell lines harboring β-catenin mutations ^[1].

HY-14719

RO4987655 5 Publications Verification CH4987655	MEK	Cancer
RO4987655 is an orally active and highly selective *MEK* inhibitor with an IC₅₀ of 5.2 nM for inhibition of *MEK1/MEK2*.

HY-15437

SL327 5+ Cited Publications	MEK	Cancer
SL327 inhibits *MEK1* and *MEK2, with IC₅₀* values of 180 nM and 220 nM, respectively.

HY-12062

PD318088 1 Publications Verification	MEK	Cancer
PD318088 is a potent, allosteric and non-ATP competitive *MEK1/2* inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research ^[1].

HY-162658

Leuxinostat	HDAC Apoptosis	Cancer
Leuxinostat is an inhibitor for HDAC with IC₅₀ of 30 nM for hHDAC6. Leuxinostat inhibits the proliferation of cells THP1, K562, U937 and MEK1, induces apoptosis in leukemia cells NB4 and MOLT-4. Leuxinostat inhibits the expansion of hematopoietic stem cells and exhibits antileukemic activity in zebrafish models ^[1].

HY-130602

MS432	PROTACs MEK	Cancer
MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for *MEK1* and *MEK2. MS432 displays good plasma exposure in mice, exhibiting DC₅₀* values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively ^[1].

HY-12042A

Pimasertib hydrochloride AS703026 hydrochloride; MSC1936369B hydrochloride	MEK	Cancer
Pimasertib hydrochloride is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor ^[1] .

HY-50295

CI-1040 20+ Cited Publications PD 184352	MEK Apoptosis	Cancer
CI-1040 (PD 184352) is an orally active, highly specific, small-molecule inhibitor of *MEK* with an IC₅₀ of 17 nM for MEK1.

HY-12042

Pimasertib 5+ Cited Publications AS703026; MSC1936369B	MEK	Cancer
Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor ^[1] .

HY-156625

Nedometinib NFX-179	MEK	Cancer
Nedometinib is a tyrosine kinase inhibitor targeting to MEK1. Nedometinib has antineoplastic effect and can be used for research in dermatosis, cutaneous fibroneuroma, neurofibromatosis ^[1].

HY-168288

MEK ligand-2	MEK Ligands for Target Protein for PROTAC	Cancer
MEK ligand-2, a **MEK1 and MEK2** inhibitor, is a ligand for target protein for PROTAC of MS934 (HY-153863). MS934 is a VHL-recruiting MEK 1/2 PROTAC degrader ^[1].

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[1] .

HY-15496

E6201 ER-806201	MEK FLT3	Cancer
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of *MEK1* and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC₅₀ value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC₅₀ value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC₅₀ value of 19 nM. Anti-tumor and anti-psoriasis efficacy ^[1] .

HY-N0776

Isorhamnetin 5+ Cited Publications 3'-Methylquercetin	MEK PI3K Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Cancer
Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of *MEK1* and PI3K.

HY-13303

RO 4927350	MEK	Cancer
RO 4927350 is a potent and selective non-ATP-competitive MEK1/2 inhibitor. RO 4927350 exhibits significant antitumor efficacy in a broad spectrum of tumor models ^[1].

HY-126048

JTP-70902	MEK	Cancer
JTP-70902, a p15 ^INK4b-inductive compound, is a *MEK1/2* inhibitor. JTP-70902 exhibits potent antitumor effect ^[1].

HY-18086

TCS PIM-1 1 4 Publications Verification SC 204330	Pim	Cancer
TCS PIM-1 1 (SC 204330) is a potent, selective and ATP-competitive *Pim-1* kianse inhibitor with an IC₅₀ of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2 (IC₅₀s >20000 nM) ^[1].

HY-15202R

Binimetinib (Standard)	MEK Autophagy	Cancer
Binimetinib (Standard) is the analytical standard of Binimetinib. This product is intended for research and analytical applications. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-10999

Trametinib 180+ Cited Publications GSK1120212; JTP-74057	MEK Autophagy Apoptosis	Cancer
Trametinib (GSK1120212; JTP-74057) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis ^[1] .

HY-12031A

U0126 Maximum Cited Publications 366 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor ^[1] .

HY-12031

U0126-EtOH Maximum Cited Publications 366 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor ^[1] .

HY-N0776R

Isorhamnetin (Standard) 3'-Methylquercetin (Standard)	MEK PI3K Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Cancer
Isorhamnetin (Standard) is the analytical standard of Isorhamnetin. This product is intended for research and analytical applications. Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of *MEK1* and PI3K.

HY-100627

APS-2-79	MEK	Cancer
APS-2-79 is a KSR-dependent *MEK* antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling ^[1].

HY-100627A

APS-2-79 hydrochloride	MEK	Cancer
APS-2-79 hydrochloride is a KSR-dependent *MEK* antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling ^[1].

HY-10999S

Trametinib-d4	MEK Autophagy Apoptosis	Cancer
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999A

Trametinib (DMSO solvate) 180+ Cited Publications GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)	MEK Apoptosis	Cancer
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis ^[1] .

HY-10999R

Trametinib (Standard)	MEK Autophagy Apoptosis	Cancer
Trametinib (Standard) is the analytical standard of Trametinib. This product is intended for research and analytical applications. Trametinib (GSK1120212; JTP-74057) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis ^[1] .

HY-10999S1

Trametinib-13C6	MEK Autophagy Apoptosis	Cancer
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-12031B

(2Z,3Z)-U0126	Others	Inflammation/Immunology
(2Z,3Z)-U0126 is a selective inhibitor of MEK1 and MEK2, demonstrating potent antiinflammatory effects by noncompetitively inhibiting AP-1 transcriptional activity with IC50 values of 72 nM for MEK1 and 58 nM for MEK2. (2Z,3Z)-U0126 also inhibits anchorage-independent growth of Ki-ras-transformed rat fibroblasts by blocking both the extracellular signal-regulated kinase and mammalian target of rapamycin pathways. Additionally, (2Z,3Z)-U0126 can undergo isomerization and cyclization, resulting in various products that show reduced affinity for MEK and diminished AP-1 inhibition compared to the parent compound.

HY-10542

GW 5074 5+ Cited Publications	Raf Apoptosis	Cancer
GW 5074 is a potent and selective c-Raf inhibitor with IC₅₀ of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms ^[1] .

HY-119272

EF24 1 Publications Verification	ERK Caspase	Cancer
EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK ^[1] .

HY-10999S2

Trametinib-13C,d3 GSK1120212-¹³C,d₃; JTP-74057-¹³C,d₃	Isotope-Labeled Compounds MEK Autophagy Apoptosis	Cancer
Trametinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

Cat. No.	Product Name	Target	Research Area

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by *MEK1* with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable ^[1].

HY-P10074

TAT-MEK1	ERK	Inflammation/Immunology
TAT-MEK1 is an inhibitor ofERK2, consisting of TAT and MEK1 (N-terminal), TAT (YGRKKRRQRRR) derived from human immunodeficiency (HIV-1) transcriptional trans activator (TAT), is a cell-penetrating peptide. TAT-MEK1 IC₅₀ in vitro for ERK2 is 29 μM ^[1] .

HY-P4136

*Myristoyl-MEK1* Derived Peptide Inhibitor 1**	ERK	Cancer
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits ERK activation with an IC₅₀ of 10 μM ^[1].

HY-P5977

*STE-MEK1(13)* Ste-MPKKKPTPIQLNP-NH₂; ERK Activation Inhibitor Peptide	ERK	Cancer
STE-MEK1(13) (Ste-MPKKKPTPIQLNP-NH ) is a cell permeable *ERK1/2* inhibitor (IC₅₀: 13-30 μM). STE-MEK1(13) inhibits ERK1/2 phosphorylation ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107417

Hypothemycin	Structural Classification Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[1] .

HY-N0776

Isorhamnetin Maximum Cited Publications 10 Publications Verification 3'-Methylquercetin	Cardiovascular Disease Flavonols Structural Classification Classification of Application Fields Source classification Hippophaë rhamnoides Plants Endogenous metabolite Flavonoids Microorganisms Leguminosae Elaeagnaceae Phenols Polyphenols Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields	MEK PI3K Endogenous Metabolite
Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of *MEK1* and PI3K.

HY-13425

Deguelin 5+ Cited Publications (-)-Deguelin; (-)-cis-Deguelin	Structural Classification Flavonoids Classification of Application Fields Leguminosae Isoflavanones Source classification Derris trifoliata Lour. Plants Disease Research Fields Biological Pesticide Research Cancer Agricultural Research	Akt Autophagy Apoptosis
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-N0226A

Epiberberine chloride 4 Publications Verification	Alkaloids Structural Classification Neurological Disease Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Source classification Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease ^[1]. Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-N0776R

Isorhamnetin (Standard) 3'-Methylquercetin (Standard)	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Hippophaë rhamnoides Plants Endogenous metabolite Flavonoids Leguminosae Elaeagnaceae Phenols Inflammation/Immunology Disease Research Fields Glycyrrhiza uralensis Fisch.	MEK PI3K Endogenous Metabolite
Isorhamnetin (Standard) is the analytical standard of Isorhamnetin. This product is intended for research and analytical applications. Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of *MEK1* and PI3K.

HY-N0226

Epiberberine	Alkaloids Source classification Ranunculaceae Coptis chinensis Franch. Plants Isoquinoline Alkaloids	Cholinesterase (ChE) Beta-secretase
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive *BACE1* inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease ^[1]. Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-113632

Debromohymenialdisine 10Z-Debromohymenialdisine	Structural Classification Natural Products Classification of Application Fields Marine natural products Sponge Disease Research Fields Cancer	Raf MEK
Debromohymenialdisine (10Z-Debromohymenialdisine) is a pyrrole alkaloid. Debromohymenialdisine has moderate inhibitory activity with an IC₅₀ value of 881 nM in the initial *Raf/MEK-1/MAPK* signaling cascade assay. Debromohymenialdisine can be used for the research of proliferation and differentiation ^[1].

Species:	Human (2) Mouse (1)
Tag:	His (1) GST (1) Flag (1)
Source:	Sf9 insect cells (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P703586

	MEK1 Protein, Human (Sf9, His) MEK1; PRKMK1	Human	Sf9 insect cells
	MEK1 Protein, Human (Sf9, His) is the recombinant human-derived MEK1, expressed by Sf9 insect cells , with His labeled tag. ,

HY-P73825

	MEK1 Protein, Mouse (sf9, His-GST) Dual specificity mitogen-activated protein kinase kinase 1; MAPKK 1; MEK 1; Map2k1	Mouse	Sf9 insect cells
	The MEK1 protein is a dual-specificity kinase that plays a crucial role in the MAP kinase pathway.MEK1 regulates various cellular processes such as growth, adhesion, survival, and differentiation, as well as transcription, metabolism, and cytoskeletal rearrangements.MEK1 Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived MEK1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P703585

	MAP2K1 Protein, Human (Sf9, Flag) MEK1; PRKMK1	Human	Sf9 insect cells
	MAP2K1 Protein, Human (Sf9, Flag) is the recombinant human-derived MAP2K1, expressed by Sf9 insect cells , with Flag labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13064S1

Cobimetinib-d4 hydrochloride
Cobimetinib-d₄ hydrochloride is deuterated labeled Cobimetinib (HY-13064). Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-10999S

Trametinib-d4
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999S1

Trametinib-13C6
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999S2

Trametinib-13C,d3
Trametinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80217

	MEK1 Antibody	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	MEK1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to MEK1. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.

HY-P80218

	MEK1/2 Antibody	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
	MEK1/2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 44 kDa, targeting to MEK1/2. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80832

	*Phospho-MEK1* (Ser298) Antibody** MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB, ICC/IF	Human, Mouse, Rat
	Phospho-MEK1 (Ser298) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to Phospho-MEK1 (Ser298). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80833

	*Phospho-MEK1* (Thr292) Antibody** MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1	WB	Mouse, Rat
	Phospho-MEK1 (Thr292) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to Phospho-MEK1 (Thr292). It can be used for WB assays with tag free, in the background of Mouse, Rat.